Wednesday, July 8, 2026

pharma · Endometrial cancer · Specific Advanced Solid Tumors · ACRV

Acrivon Therapeutics

Acrivon Therapeutics clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Cambridge, USA HQ
2018 Founded
84 Employees
Public company Type
ACRV · NYSE Ticker
Company details
Status
Public
HQ
Cambridge, USA
Founded
2018
Employees
84
Programs
4
Drugs
3
Patents
0
Intelligence · Clinical Programs

Acrivon Therapeutics projects

4 ClinicalTrials.gov programs sponsored by Acrivon Therapeutics.

Acrivon Therapeutics has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. ACR-368

    Acrivon Therapeutics

    Endometrial Adenocarcinoma

    phase 2 small molecule active

    1 trial
  2. ACR-368-201

    Acrivon Therapeutics

    Endometrial cancer

    phase 2 small molecule active

    1 trial
  3. Gemcitabine

    Acrivon Therapeutics

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial
  4. ACR-2316

    Acrivon Therapeutics

    Specific Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Acrivon Therapeutics have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.